This session will introduce the main themes of the section action-oriented participatory research methods from the new SAGE Handbook of Participatory Research and Inquiry.
New SAGE Handbook of Participatory Research and Inquiry - Institute of Development Studies ids.ac.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ids.ac.uk Daily Mail and Mail on Sunday newspapers.
Children who use violence in the home is a form of domestic violence that’s not often spoken about, but one woman who spoke with The Feed wants more people to share their stories.
Oral medication effective for treating sickle cell disease, study shows
DEVELOPMENT: Sickle cell disease mainly affects people from African and Caribbean backgrounds
A STUDY has uncovered that taking medicine orally is one of the most effective ways of treating sickle cell disease (SCD).
Phase 3 of the recently published HOPE study, revealed in Lancet Haematology that treatment with an oral medication – Oxbryta – resulted in rapid and lasting improvements in the levels of red blood cells throughout 72 weeks of treatment for the 274 participants involved.
Oxbryta is an oral and once-daily therapy, which directly inhibits the destruction of haemoglobin – a protein found in red blood cells – which is the root cause of the sickling and destruction of red blood cells with SCD.
Global Blood Therapeutics, Inc.: Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patient (voxelotor) Tablets
Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin s affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes Oxbryta blocks polymerization and the resultant sickling and destruction of red blood cells, which are primary pathologies faced by every single person living with SCD. Through addressing hemolytic anemia and improving oxygen delivery throughout the body, GBT believes that Oxbryta has the potential to modify the course of SCD. On Nov. 25, 2019, Oxbryta received U.S. Food and Drug Administration (FDA) accelerated approval for the treatment of SCD in adults and children 12 years of age and